IS8332A - Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma - Google Patents

Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma

Info

Publication number
IS8332A
IS8332A IS8332A IS8332A IS8332A IS 8332 A IS8332 A IS 8332A IS 8332 A IS8332 A IS 8332A IS 8332 A IS8332 A IS 8332A IS 8332 A IS8332 A IS 8332A
Authority
IS
Iceland
Prior art keywords
olmesartan
eprosartan
telmisartan
candesartan
valsartan
Prior art date
Application number
IS8332A
Other languages
English (en)
Other versions
IS2534B (is
Inventor
Almirante Nicoletta
Del Soldato Piero
Ongini Ennio
Original Assignee
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox S.A. filed Critical Nicox S.A.
Publication of IS8332A publication Critical patent/IS8332A/is
Publication of IS2534B publication Critical patent/IS2534B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS8332A 2003-07-31 2006-02-27 Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma IS2534B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102379 2003-07-31
PCT/EP2004/051550 WO2005011646A2 (en) 2003-07-31 2004-07-20 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
IS8332A true IS8332A (is) 2006-02-27
IS2534B IS2534B (is) 2009-08-15

Family

ID=34112476

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8332A IS2534B (is) 2003-07-31 2006-02-27 Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma

Country Status (29)

Country Link
US (1) US20060276523A1 (is)
EP (1) EP1653950B1 (is)
JP (1) JP2007500684A (is)
KR (1) KR20060056352A (is)
CN (1) CN100496490C (is)
AR (1) AR045145A1 (is)
AT (1) ATE383155T1 (is)
AU (1) AU2004260830B2 (is)
BR (1) BRPI0413028A (is)
CA (1) CA2534451A1 (is)
CY (1) CY1110447T1 (is)
DE (1) DE602004011230T2 (is)
DK (1) DK1653950T3 (is)
EC (1) ECSP066334A (is)
ES (1) ES2299861T3 (is)
HR (1) HRP20060084A2 (is)
IL (1) IL172703A0 (is)
IS (1) IS2534B (is)
MA (1) MA27987A1 (is)
MX (1) MXPA06001263A (is)
NO (1) NO20060900L (is)
NZ (1) NZ544463A (is)
PL (2) PL1653950T3 (is)
PT (1) PT1653950E (is)
RU (1) RU2374240C2 (is)
SI (1) SI1653950T1 (is)
UA (1) UA87983C2 (is)
WO (1) WO2005011646A2 (is)
ZA (1) ZA200600856B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008196A1 (en) * 2004-07-20 2006-01-26 Nicox S.A. Process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates, intermediates useful in said process and preparation thereof
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
RU2306930C1 (ru) * 2005-12-28 2007-09-27 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции комбинацией лозартана и l-аргинина при l-name-индуцированном дефиците оксида азота
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑-5-羧酸类衍生物、制备方法及其应用
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
EP2103610B1 (en) * 2006-12-06 2011-09-21 Shanghai Allist Pharmaceutical., Inc. Salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof
CA2671421A1 (en) * 2006-12-13 2008-06-26 Merck & Co., Inc. Nitroderivatives as angiotensin ii receptor antagonists
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1980559A1 (en) * 2007-04-10 2008-10-15 CTG Pharma S.r.l. Cardiovascular agents
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
EP2534957B1 (en) 2007-12-14 2015-05-27 AeroDesigns, Inc Delivering aerosolizable products
CA2711134A1 (en) * 2008-01-24 2009-07-30 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
CA2711461A1 (en) 2008-02-08 2009-08-13 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
WO2009106471A2 (en) * 2008-02-26 2009-09-03 Nicox S.A. New angiotensin ii receptor blocker derivatives
CA2712689A1 (en) * 2008-02-26 2009-09-03 Nicoletta Almirante Angiotensin ii receptor antagonists
JP2011523941A (ja) * 2008-05-15 2011-08-25 メルク・シャープ・エンド・ドーム・コーポレイション アンギオテンシンii受容体アンタゴニスト
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
AU2009256822A1 (en) * 2008-06-09 2009-12-17 Nicox S.A. Angiotensin II receptor antagonists
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) * 2008-08-08 2010-02-11 Nicox S.A. Angiotensin ii receptor antagonists
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
JP2012511002A (ja) * 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンii受容体アンタゴニストとしてのニトロオキシ誘導体
SG173044A1 (en) 2009-01-23 2011-08-29 Hanmi Holdings Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
AR080925A1 (es) 2010-04-19 2012-05-16 Cardiolynx Ag Derivados de valsartan que portan donadores de no para el tratamiento de las enfermedades vasculares y metabolicas
AU2011243947A1 (en) * 2010-04-23 2012-12-06 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
US9844599B2 (en) 2013-01-21 2017-12-19 Apparao Satyam Nitric oxide releasing produgs of therapeutic agents
CN103275074B (zh) * 2013-06-21 2016-08-10 黄冈鲁班药业股份有限公司 一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) * 2015-01-09 2018-12-07 北京中医药大学 一种用于治疗高血压的化合物及其制备方法和用途
WO2017041701A1 (zh) 2015-09-07 2017-03-16 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
RU2067581C1 (ru) * 1989-06-30 1996-10-10 Е.И.Дюпон Де Немур Энд Компани Аралкилзамещенные имидазолы, обладающие противогипертоническим действием, способ их получения и фармацевтический состав, обладающий ингибирующей активностью в отношении ангиотензина ii
KR0163595B1 (ko) * 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
AT398202B (de) * 1991-10-04 1994-10-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie

Also Published As

Publication number Publication date
DK1653950T3 (da) 2008-05-26
AR045145A1 (es) 2005-10-19
ECSP066334A (es) 2006-07-28
CN100496490C (zh) 2009-06-10
AU2004260830A1 (en) 2005-02-10
EP1653950B1 (en) 2008-01-09
ES2299861T3 (es) 2008-06-01
MA27987A1 (fr) 2006-07-03
IS2534B (is) 2009-08-15
PL1653950T3 (pl) 2008-08-29
PL379420A1 (pl) 2006-09-04
RU2374240C2 (ru) 2009-11-27
PT1653950E (pt) 2008-04-11
DE602004011230D1 (de) 2008-02-21
ZA200600856B (en) 2007-05-30
CY1110447T1 (el) 2015-04-29
HRP20060084A2 (hr) 2006-04-30
EP1653950A2 (en) 2006-05-10
DE602004011230T2 (de) 2009-01-02
WO2005011646A3 (en) 2005-04-21
ATE383155T1 (de) 2008-01-15
HK1095093A1 (zh) 2007-04-27
MXPA06001263A (es) 2006-04-11
SI1653950T1 (sl) 2008-06-30
JP2007500684A (ja) 2007-01-18
CA2534451A1 (en) 2005-02-10
NO20060900L (no) 2006-02-24
KR20060056352A (ko) 2006-05-24
US20060276523A1 (en) 2006-12-07
RU2006105804A (ru) 2007-09-20
IL172703A0 (en) 2006-04-10
UA87983C2 (ru) 2009-09-10
AU2004260830B2 (en) 2010-04-29
NZ544463A (en) 2009-10-30
BRPI0413028A (pt) 2006-10-03
CN1832742A (zh) 2006-09-13
WO2005011646A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
IS2534B (is) Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma
IL184900A0 (en) Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
IL195797A0 (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
IL181550A0 (en) Purification of olmesartan medoxomil
IL195279A0 (en) 1,5-diphenylpyrazoles ii as hsp90 inhibitors
GB2454620B (en) Solid dosage form of olmesartan medoxomil and amlodipine
IL197934A (en) History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
ZA200810474B (en) Tablets comprising candesartan cilexetil
IL185726A0 (en) Benzimidazole derivative and use as angiotensin ii antagonist
EP1907369A4 (en) THIAZOLE DERIVATIVES USEFUL AS AMPK ACTIVATORS
ZA200705068B (en) Hydantoin derivatives useful as metalloproteinase inhibitors
IL178100A0 (en) 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
EP2036895A4 (en) HSP90 INHIBITOR
IL176630A0 (en) Benzimidazole derivatives
IL188486A0 (en) Benzimidazole derivatives as 5-ht6,5-ht24
CL2004000379A1 (es) Uso de una combinacion farmaceutica de lercanidipina con un bloqueador de los receptores de angiotensina ii, seleccionado de olmesartan, irbesartan, valsartan, telmisartan y losartan, para tratar la hipertension.
IL176140A0 (en) Candesartan cilexetil polymorphs
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
EP1778650A4 (en) PROCESS OF MANUFACTURING CANDÉSARTAN CILEXÉTIL
EP1984356A4 (en) IMPROVED PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
WO2006063578A3 (de) Verfahren zur herstellung von candesartan
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors
ZA200800892B (en) Activator of peroxisome proliferator activated receptor δ
ZA200709002B (en) Benzimidazole derivative and use as angiotensin II antagonist